IRIS
GRAGNANO, Felice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.460
NA - Nord America 1.334
AS - Asia 316
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
SA - Sud America 2
Totale 3.127
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.326
IE - Irlanda 773
IT - Italia 176
GB - Regno Unito 169
SG - Singapore 145
CN - Cina 125
DE - Germania 75
FR - Francia 66
GR - Grecia 53
UA - Ucraina 47
SE - Svezia 31
FI - Finlandia 29
BE - Belgio 17
IN - India 13
TR - Turchia 13
ES - Italia 8
CA - Canada 6
EG - Egitto 6
NL - Olanda 5
KR - Corea 4
AU - Australia 3
CZ - Repubblica Ceca 3
EU - Europa 3
PK - Pakistan 3
AR - Argentina 2
ID - Indonesia 2
MY - Malesia 2
PL - Polonia 2
TN - Tunisia 2
TW - Taiwan 2
VN - Vietnam 2
AN - Antille olandesi 1
AT - Austria 1
DK - Danimarca 1
HK - Hong Kong 1
IL - Israele 1
IR - Iran 1
JP - Giappone 1
MA - Marocco 1
MK - Macedonia 1
MX - Messico 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 3.127
Salva come PNG Salva come JPEG
Città #
Dublin 761
Chandler 363
Jacksonville 100
Princeton 95
Roxbury 95
Singapore 92
New York 91
Beijing 64
Cambridge 50
Medford 48
Bremen 45
Des Moines 33
Boardman 29
Ann Arbor 26
Caserta 26
Wilmington 24
Ashburn 18
Lappeenranta 18
Brussels 17
Nanjing 14
Naples 12
Houston 11
Napoli 10
Helsinki 9
Hyderabad 9
Norwalk 8
Sivas 8
Milan 6
San Giovanni In Fiore 6
Woodbridge 6
Jinan 5
Menlo Park 4
Shenyang 4
Amsterdam 3
Andover 3
Burbank 3
Casier 3
Duncan 3
Fairfield 3
Giugliano In Campania 3
Hebei 3
Nanchang 3
Padova 3
Philadelphia 3
Pune 3
Redwood City 3
Vic 3
Acerra 2
Acquafredda 2
Adelfia 2
Bari 2
Brno 2
Cairo 2
Calgary 2
Camden 2
Capannelle 2
Catamarca 2
Chiayi County 2
Dearborn 2
Dishna 2
Dong Ket 2
Eboli 2
Edinburgh 2
Florence 2
Giza 2
Hangzhou 2
Hefei 2
Karachi 2
Kraków 2
Loreto Aprutino 2
Los Angeles 2
Malang 2
Modugno 2
Montreal 2
Oristano 2
Palermo 2
Paris 2
Penang 2
Pimonte 2
Piombino 2
Pozzuoli 2
Sala Consilina 2
San Mateo 2
Shenzhen 2
Taiyuan 2
Tunis 2
Zhengzhou 2
Agordo 1
Bacau 1
Belgrade 1
Brantford 1
Brdo 1
Brunswick 1
Carinaro 1
Casablanca 1
Casagiove 1
Casoria 1
Chicago 1
Daegu 1
Düsseldorf 1
Totale 2.242
Salva come PNG Salva come JPEG
Nome #
MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients 83
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 78
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 59
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 57
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 55
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 53
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 52
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 51
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 47
Von Willebrand Factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target 45
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 45
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team 45
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 44
[The COMPASS study] 44
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 44
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 43
Are we ready for a gender-specific approach in interventional cardiology? 43
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 42
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 42
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 41
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial 40
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 40
Early-onset MINOCA: Prognostic implications and considerations for practice 40
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest 39
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 39
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 39
Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience 38
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up 38
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition 38
Natural history of left ventricular hypertrophy in infants of diabetic mothers 38
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 36
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy 36
From Femoral to Radial Approach in Coronary Intervention: Review of the Literature and 6 Years Single-Center Experience 35
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 35
Anticoagulation After Primary PCI: The Land of Promises and Uncertainty 35
von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications 34
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry 34
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 34
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 34
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 33
Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy 32
Simulation Models of Therapy Intensification in Lipid-Lowering Medicine: Fact or Fantasy? 32
Cognitive Function in a Randomized Trial of Evolocumab 32
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 32
Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise 32
A call for action in bleeding prevention 32
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018) 31
Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome 31
CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach? 31
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial 30
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 30
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 29
[Evaluation and percutaneous treatment of severely calcified coronary lesions] 29
Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines 28
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 28
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 28
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry 27
Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News? 27
Letter by Calabro and Gragnano Regarding Article, "Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials" 27
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 27
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials 27
Prognostic implications of ischemia with nonobstructive coronary arteries (INOCA): Understanding risks for improving treatment 27
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team 25
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial 24
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 23
Event recurrence after myocardial infarction: Prediction is very difficult, especially about the future 23
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 23
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 23
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 23
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 23
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 23
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies 22
Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis 22
[Device therapy in chronic heart failure: a case of hypertrophic cardiomyopathy treated with cardiac contractility modulation therapy] 21
Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? 21
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 21
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY 21
The benefit and harm of treating STEMI: Between ischemia, bleeding, and reperfusion injury 21
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 20
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 20
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes 20
Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter 20
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation 20
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 20
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 19
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 19
Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future perspectives 19
Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome 19
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease 19
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial 19
Terapie antitrombotiche in pazienti con infezione da SARS-CoV-2: Dalle attuali evidenze alle ragionevoli raccomandazioni – Position paper del gruppo di studio aterosclerosi, trombosi e biologia vascolare 18
Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology 18
Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria 18
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 18
[Gut microbiota and the cardiovascular system: current evidence and future perspectives] 18
Physiology-guided revascularization of non-culprit lesions in patients with STEMI: Could vFFR be the way? 17
Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias? 17
Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: The RE-SCORE multicentre prospective registry 17
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial 16
Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome 14
Totale 3.161
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.414
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.414
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020219 35 26 12 9 19 6 39 18 25 15 13 2
2020/2021286 6 0 7 40 33 2 61 11 19 13 62 32
2021/2022784 10 1 8 28 196 11 12 121 21 94 60 222
2022/20231.348 130 74 33 93 123 73 4 70 680 8 27 33
2023/2024743 44 21 23 38 194 110 54 6 7 33 54 159
2024/20257 7 0 0 0 0 0 0 0 0 0 0 0
Totale 3.540